City is major spy hub. Markets pointing higher, dow industrials up 52 and the nasdaq up 39 and s p 500 higher by ten minutes. The dow moved 560 points between highs and lows, the Technology Startup set for a big price tag as it readies to go public with offering next week. We have all the numbers coming up. Speaking of tech, amazon unveiled a whole new slew of gadgets to boost gaming experience. Candy craze, more americans are stocking up halloween candy despite no worries of trick or treating this year. Mornings with maria is live right now. Take a look at indices. Things have worsen in the last few moments. Markets in europe poise today see the worst week in june as uk reports rise in coronavirus cases. Mixed story in asia as well,ation markets finishing flat but a mixed story. Japan and korea were up. Hong kong and shanghai were lower. Some of the top stories that we are watching out right now. President trump handing out drug discount cards to seniors as he lays out to America Firs
Border security and also serves on budget. Thanks for being here. Guest i am thrilled to be here. Host freshman democrat. The president , i know you are in support of what president obama did with the d. A. C. A. Program. President trump has decided to rescind it. Then he sends out this tweet yesterday. Congress has now had six months to legalize d. A. C. A. Something the Obama Administration was unable to do. If they cant, i will revisit this issue. Some are saying the president could make a deal on d. A. C. A. Or some sort of dream act. Guest yes. The thing is, he has been very confusing. I think a lot of our d. A. C. A. Students across the country actually thought that they were going to get a president that would keep d. A. C. A. Because he said a number of things during the campaign and as president about his big heart. I think it was fairly manipulative to end d. A. C. A. In this way and also irresponsible. What he is acknowledging in that tweet is that if congress cant get it do
Arrangement, and are you guaranteeing what is the price of the drug when are you saying you are only going to get paid x if you reach a cure level or certain level of adherence. Theres some interference there, and its used as an excuse for those types of arrangement or getting out of those arrangements by pharmaceutical companies. The other is the fda approves the drug if it works. And they dont necessarily approve it saying whether it works better than things that have previously been approved or whether it doesnt work better than thing previously approved. And that can create some friction when it comes to dealing with providers who seem to want to gravitate toward the newest and the latest, even if it really doesnt turn out to work any better than some of the alternatives that have come down the pike before. So whats the solution there . More as we heard on the earlier panel, more effectiveness, information and data . I think the comparative effectiveness would really help. Then you
Providing low income service. Sort of almost to make it politically good, not just politically acceptable, politically good for a company to price discriminate. I wasnt sure where you were headed with that. I cant think of what it is right now. But if they were to take samples of fingerprints that are on some of those voluntary agreements, you might find fingerprints somewhere. Thats good. I think thats great. The programs are there. Just one thing, back to yesterdays conversation. He said the one thing about the act is it allowed competition to enter. What the competition did, is before the telecomact, the prices that we had didnt make a whole lot of sense. All kinds of different cross subsidies. 25 cents a minute long distance. And what the competition did is forced all those prices to get rationalized. The High Cost Fund kind of impedes that whole process. One thing, theres really i think the benefits in terms of incentives for investment and those other things in the high cost area
And coming up, more on the recent health and Human Services forum on pharmaceutical innovation and drug costs. Up next, senators from medicare and medicaid acting administrator andy slavit and purchasing strategies for the pharmaceutical industries. This includes manufacturers, employers, consumers, Health Insurance providers and government officials. Once again, if you will all take your seats well get started on the final panel of the day. Where as promised, well devote our discussion to outcomes based purchasing, what is the potential for those, what are the obstacles and how do we get to better value and better accessibility for patients as soon as possible through these and other mechanisms. Let me introduce our panelists now. You have been introduced to at least this gentleman there, dan durham, Senior Vice President of ahib, thats americas Health Insurance plans. And ken frazier is with us, the president and chief executive officer of merck and company. One of the premier pharma